Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SNYNF save search
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
Published: 2024-03-19 (Crawled : 12:00) - globenewswire.com
SNYNF | $92.966 630
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
MORF | $28.31 -4.07% 160K
|
Health Technology
|
| O: -1.58%
H: 5.18%
C: 2.95%
cooper medical simon
Innate Pharma Announces Its Participation to Upcoming Investor Conference - March 19, 2024
Published: 2024-03-19 (Crawled : 08:00) - biospace.com/
SNYNF | $92.966 630
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
IPHA | $2.42 6K
|
Health Technology
|
| O: 0.84%
H: 4.56%
C: 0.83%
pharma conference
Global Neutropenia Market Poised to Reach USD 5.86 Billion by 2028, Amid Rising Cancer Incidence and Advancements in Treatment Options
Published: 2024-03-18 (Crawled : 00:00) - prnewswire.com
SNYNF | $92.966 630
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
BAX | $39.79 -0.62% 1.3M
|
Health Technology
|
| O: 0.02%
H: 1.03%
C: 0.96%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
GILD | $67.44 -0.46% 2.3M
|
Health Technology
|
| O: 0.11%
H: 0.59%
C: 0.1%
BIIB | $196.6 -0.1% 350K
|
Health Technology
|
| O: -0.48%
H: 0.31%
C: 0.13%
reach cancer treatment global market
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
Published: 2024-03-19 (Crawled : 00:00) - prnewswire.com
SNYNF | $92.966 630
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
ibi302 macular trial
FDA Approves First Gene Therapy for Rare Pediatric Disease
Published: 2024-03-18 (Crawled : 23:00) - biospace.com/
PRGO A | $30.025 -0.35% 710K
|
Health Technology
|
| O: 0.33%
H: 0.13%
C: -1.51%
JNJ | $145.405 -1.48% 7.6M
|
Health Technology
|
| O: 0.2%
H: 0.08%
C: -1.14%
ABT | $109.92 0.95% 3.2M
|
Health Technology
|
| O: 1.71%
H: 0.36%
C: -2.52%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: -0.81%
H: 0.0%
C: 0.0%
fda rare first disease therapy
GRO Biosciences Expands Executive Team with Appointment of Biopharma Veteran Tracey Lodie, PhD as Chief Development Officer
Published: 2024-03-18 (Crawled : 12:00) - biospace.com/
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: -0.81%
H: 0.0%
C: 0.0%
biopharma
World Cancer Immunotherapy Market Research 2023-2027: Curing Cancer is Generating Enormous New Opportunities - Outcome Potential, Technology Environment, Target Solutions
Published: 2024-03-16 (Crawled : 04:20) - prnewswire.com
BIIB | $196.6 -0.1% 350K
|
Health Technology
| Email alert
Add to watchlist
SNY | $46.19 0.57% 580K
|
Health Technology
| Email alert
Add to watchlist
JNJ | $145.405 -1.48% 7.6M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | $92.966 630
|
Health Technology
| Email alert
Add to watchlist
world cancer research solutions immunotherapy technology market
Sanofi: Information concerning the total number of voting rights and shares - February 2024
Published: 2024-03-15 (Crawled : 19:00) - globenewswire.com
SNY | $46.19 0.57% 580K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | $92.966 630
|
Health Technology
| Email alert
Add to watchlist
total
Madrigal’s Rezdiffra, BMS’s Breyanzi Lead Week of Landmark FDA Approvals
Published: 2024-03-15 (Crawled : 15:00) - biospace.com/
PRGO A | $30.025 -0.35% 710K
|
Health Technology
|
| O: -0.62%
H: 0.59%
C: -1.01%
JNJ | $145.405 -1.48% 7.6M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
ABT | $109.92 0.95% 3.2M
|
Health Technology
|
| O: -5.53%
H: 0.0%
C: 0.0%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
fda breyanzi week
Prefilled Syringes Market, Industry Trends and Global Forecasts, 2035 - Surge in Dual Chamber Format Adoption Amid Growing Player Base
Published: 2024-03-15 (Crawled : 14:30) - prnewswire.com
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
global trends growing
Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
Published: 2024-03-15 (Crawled : 14:30) - prnewswire.com
TAK | $13.235 0.42% 710K
|
Health Technology
|
| O: 0.21%
H: 0.97%
C: 0.7%
NVS | $92.99 -1.5% 990K
|
Health Technology
|
| O: 0.05%
H: 0.14%
C: -0.93%
JNJ | $145.405 -1.48% 7.6M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
LLY | $749.215 -0.21% 1.4M
|
Health Technology
|
| O: -0.7%
H: 0.73%
C: -0.16%
ABBV | $163.42 1.08% 2M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
REGN | $895.92 -0.29% 310K
|
Health Technology
|
| O: -0.27%
H: 1.26%
C: 0.84%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: 0.2%
H: 1.14%
C: -1.18%
antibody therapeutics market
Insulin Market size to grow by USD 1.67 billion from 2022 to 2027, North America accounts for 38% of the market growth, Technavio
Published: 2024-03-15 (Crawled : 02:00) - prnewswire.com
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
america insulin market
Blood Glucose Monitoring Devices Market Size, Share & Trends Analysis Report 2024-2030: The Self-monitoring Devices Segment Held the Largest Revenue Share of 66% in 2023
Published: 2024-03-14 (Crawled : 23:00) - prnewswire.com
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
report revenue blood trends market
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
Published: 2024-03-14 (Crawled : 21:00) - globenewswire.com
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
CTSO | $0.83 -4.25% 81K
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: -8.33%
year results
Full-year 2024 guidance suspended due to the temporary pause of API production at the Brindisi site in Italy
Published: 2024-03-14 (Crawled : 18:00) - globenewswire.com
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
italy
Biopharma Layoff Tracker 2024: Spruce, Coherus, Takeda and More Cut Staff
Published: 2024-03-14 (Crawled : 15:30) - biospace.com/
RLYB | $1.745 -4.65% 590K
|
|
| O: 0.28%
H: 6.82%
C: -9.38%
JNJ | $145.405 -1.48% 7.6M
|
Health Technology
|
| O: -1.04%
H: 0.0%
C: 0.0%
VXRT | $0.883 -2.87% 520K
|
Health Technology
|
| O: -1.77%
H: 2.03%
C: -0.9%
TXMD | $1.9899 34K
|
Health Technology
|
| O: -0.84%
H: 2.97%
C: 0.0%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
PTCT | $25.58 -0.39% 280K
|
Health Technology
|
| O: -1.4%
H: 0.0%
C: -4.84%
NKTR | $1.495 -4.78% 980K
|
Health Technology
|
| O: 2.35%
H: 2.3%
C: -1.15%
MOR | $17.985 -0.19% 330K
|
Health Technology
|
| O: -0.5%
H: 0.84%
C: -0.06%
GLPG | $29.495 -1.02% 150K
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: -1.44%
AMRN | $0.9 -2.03% 500K
|
Health Technology
|
| O: 0.83%
H: 2.26%
C: -5.55%
GOOGL | $154.86 12M
|
Technology Services
|
| O: 1.0%
H: 1.7%
C: 1.35%
GOOG | $156.33 8.7M
|
Technology Services
|
| O: 1.09%
H: 1.71%
C: 1.43%
OCX | $2.65 4.74% 130K
|
Health Technology
|
| O: 0.0%
H: 1.0%
C: -1.99%
biopharma
D3 Bio Appoints Dr. Antoine Yver as Independent Board Member
Published: 2024-03-14 (Crawled : 14:30) - prnewswire.com
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
Constellation Appoints New Chief Financial Officer, Daniel Bisgeier
Published: 2024-03-14 (Crawled : 13:00) - prnewswire.com
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
financial
Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officer
Published: 2024-03-14 (Crawled : 12:30) - biospace.com/
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
financial
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
Published: 2024-03-14 (Crawled : 10:00) - globenewswire.com
FWBI | $3.27 17K
|
Manufacturing
|
| O: -3.52%
H: 0.16%
C: -14.76%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
first business pipeline biopharma
Gainers vs Losers
| 54% | 46% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
JAGX | $0.1771 49.07% 540M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
MCBC | $13.74 38.37% 1.6M
|
Finance
PALI | $5.51 32.45% 28M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.